Albert David Share Price & Earnings Call Analysis

Financials of Albert David

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Albert David

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +81929388898998837571879086
Expenses +72797780798892828081857983
Operating Profit101316810161-5-113113
OPM %12%14%17%9%11%1%6%1%-6%-15%3%12%3%
Other Income +0181217102321-9-522-212-25
Interest0000000001110
Depreciation2212222222223
Profit before tax7292723182225-10-128-320-25
Tax %48%20%24%20%29%15%28%-8%-13%6%28%23%-15%
Net Profit +4232019131918-9-108-315-21
EPS in Rs6.5441.1635.5732.8022.6233.0131.66-16.45-18.1013.91-5.7826.81-37.55

Financials of Albert David

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +317318293285316320246313341362345334
Expenses +281286266267286289227272297315342328
Operating Profit3731271830301941444735
OPM %12%10%9%6%10%10%8%13%13%13%1%2%
Other Income +2438915717161558307
Interest321111111013
Depreciation15988788997710
Profit before tax20632618382927475197251
Tax %32%24%39%45%29%34%19%25%29%22%32%379%
Net Profit +1448161027192235367517-1
EPS in Rs24.0084.1027.9617.2446.6833.5938.7961.7863.38132.1530.14-2.61
Dividend Payout %23%7%20%32%13%21%15%15%14%9%17%-192%

Financials of Albert David

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital666666666666
Reserves87131177180205217239274306377387386
Borrowings +302030280226531230
Other Liabilities +7167717684959511610611210798
Total Liabilities193224285290295320341401423498511519
Fixed Assets +4944878377918488808399100
CWIP5595521137221
Investments16485968113122138183193273260243
Other Assets +12212713013499106119130148135151155
Total Assets193224285290295320341401423498511519

Financials of Albert David

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +28682030323037401146-28-8
Cash from Investing Activity +-9-38-36-11-19-20-37-40-5-3323-4
Cash from Financing Activity +-18-187-5-17-10-2-2-6-8012
Net Cash Flow112-1015-40-2-1-14-5-0
Free Cash Flow1862-03145153532635-43-36
CFO/OP95%303%115%204%126%149%202%129%59%131%-629%-49%

Financials of Albert David

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days474141352534292932302937
Inventory Days176187217173151148151124149126201187
Days Payable103102117127102132104969598118104
Cash Conversion Cycle12012614181745076578758112120
Working Capital Days272524102118-10-3414-136247
ROCE %18%17%15%7%18%14%12%17%17%28%6%1%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd